On the 6th of April 2024, ASHM Health organised a national workshop, funded by ViiV Healthcare, to convene a select group of key stakeholders from each Australian state and territory. The primary objective was to facilitate discussions around how to successfully implement the use of long-acting injectable cabotegravir (CAB-LA) as HIV PrEP throughout Australia and to identify the requisite support needed within the healthcare sector to navigate this transformative change in HIV biomedical prevention.
As Australia hopes to introduce CAB-LA into clinical practice, it is essential to engage in proactive discussions and planning to ensure a smooth transition and optimise the benefits of this new prevention modality.
A summary of the key discussions and recommendations from the full-day workshop have been collected in the Implementing long-acting injectable HIV pre-exposure prophylaxis using Cabotegravir-LA: Recommendations to support the Australian Health Sector Workshop Summary Report.
Current considerations and guidelines around long-acting injectable PrEP can be found on the National PrEP Guidelines website.
